Article

Regeneron, Bayer launch trial of aflibercept for CNV

Regeneron and Bayer HealthCare have begun a Phase III clinical trial in collaboration with the Singapore Eye Research Institute (SERI) to investigate the efficacy and safety of aflibercept ophthalmic solution (VEGF Trap-Eye) in patients with choroidal neovascularization (CNV) of the retina as a result of pathologic myopia.

Tarrytown, NY, Berlin, and Singapore-Regeneron and Bayer HealthCare have begun a phase III clinical trial in collaboration with the Singapore Eye Research Institute (SERI) to investigate the efficacy and safety of aflibercept ophthalmic solution (VEGF Trap-Eye) in patients with choroidal neovascularization (CNV) as a result of pathologic myopia. The trial has started in Japan and other Asian countries, including China, Korea, Singapore, and Taiwan.

Aflibercept previously has met its primary efficacy endpoint in a phase III trial for neovascular age-related macular degeneration.

SERI has been appointed as the Asian reading center partner for this study. The Singapore Advanced Imaging Laboratory for Ocular Research (SAILOR) will serve as the first reading center for the aflibercept studies in the region.

“Myopia is a common problem in Singapore and Asia. In particular, myopic CNV, which affects certain groups of people with higher degrees of myopia, may lead to vision loss,” said Wong Tien Yin, MBBS, PhD, MMed, MPH, FRCS, FRANZCO, director of SERI and co-director of SAILOR. “There remains uncertainty regarding the best methods of treatment for myopic CNV, and this new trial will go toward addressing this clinical need.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.